Acorda Therapeutics, Inc. (ACOR) revealed the resubmission of its New Drug Application, or NDA, for Fampridine-SR to the U.S. Food and Drug Administration.
Fampridine-SR is a novel therapy being developed to improve walking ability in people with multiple sclerosis. Acorda received a Refuse to File letter for the Fampridine-SR NDA on March 30, 2009, which cited the need to correct "format issues" and requested additional supporting information before the NDA could be accepted for review.
Based on subsequent discussions with the FDA, Acorda has resubmitted the Fampridine-SR NDA and believes that all of the Agency's comments related to the RTF have been addressed.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.